MCC950 targets the ROS-NEK7-NLRP3 axis to improve type 2 diabetic retinopathy.

ABSTRACT: 1 mM of MCC950 targets the ROS-NEK7-NLRP3 axis to ameliorate T2DM in rats and exhibits peak efficacy in improving retinopathy. It has been found that the specific inhibitor MCC950 can alleviate diabetic retinopathy by inhibiting NLRP3 inflammasome, but its concentration-dependent efficacy on retinal pathology needs to be explored. The aim of this study was to quantify the effects of intravitreal injection of graded concentrations of MCC950 (0.01, 0.1, 1,10 mM) on retinal structure and NLRP3 inflammasome signalling in type 2 diabetic male rats, and to reveal that 1 mM MCC950 may exert optimal retinoprotective effects by down-regulating the NEK7-NLRP3 pathway. Type 2 diabetic male rats induced by streptozotocin were administered intravitreal injections of MCC950 at varying concentrations (0.

SUBMITTER: Ren K 

PROVIDER: S-EPMC12457656 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature